- Home
- VRNA vs MEDP Comparison
VRNA vs MEDP Comparison
Compare VRNA & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- MEDP
- Stock Information
- Founded
- VRNA 2005
- MEDP 1992
- Country
- VRNA United Kingdom
- MEDP United States
- Employees
- VRNA N/A
- MEDP N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- Sector
- VRNA Health Care
- MEDP Health Care
- Exchange
- VRNA Nasdaq
- MEDP Nasdaq
- Market Cap
- VRNA 8.3B
- MEDP 8.5B
- IPO Year
- VRNA 2017
- MEDP 2016
- Fundamental
- Price
- VRNA $105.79
- MEDP $472.94
- Analyst Decision
- VRNA Buy
- MEDP Hold
- Analyst Count
- VRNA 11
- MEDP 10
- Target Price
- VRNA $114.10
- MEDP $406.89
- AVG Volume (30 Days)
- VRNA 1.4M
- MEDP 334.8K
- Earning Date
- VRNA 08-06-2025
- MEDP 10-20-2025
- Dividend Yield
- VRNA N/A
- MEDP N/A
- EPS Growth
- VRNA N/A
- MEDP 26.42
- EPS
- VRNA N/A
- MEDP 13.46
- Revenue
- VRNA $221,673,000.00
- MEDP $2,231,787,000.00
- Revenue This Year
- VRNA $896.59
- MEDP $19.01
- Revenue Next Year
- VRNA $77.56
- MEDP $8.88
- P/E Ratio
- VRNA N/A
- MEDP $35.17
- Revenue Growth
- VRNA N/A
- MEDP 9.94
- 52 Week Low
- VRNA $24.50
- MEDP $250.05
- 52 Week High
- VRNA $105.89
- MEDP $501.30
- Technical
- Relative Strength Index (RSI)
- VRNA 68.01
- MEDP 67.01
- Support Level
- VRNA $105.23
- MEDP $452.77
- Resistance Level
- VRNA $105.81
- MEDP $475.77
- Average True Range (ATR)
- VRNA 0.25
- MEDP 9.21
- MACD
- VRNA -0.36
- MEDP -2.54
- Stochastic Oscillator
- VRNA 87.88
- MEDP 92.74
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.